Joel Litman and the Hidden Alpha team believe that Steve Jobs’ “Final Prophecy” may be unfolding right in front of our eyes. But are they really on to something? Read on for a look into Jobs’ last prediction and the team’s latest research package.
What Is Steve Jobs’ “Final Prophecy?”
Before his passing, Steve Jobs made a final prediction that an emerging tech could spark breakthroughs in key industries across the globe.
Some industries that Apple’s co-founder believed would be affected include healthcare, automotives, renewable energy, and much more.
We’re not talking about the typical technology everyone is already investing in. Steve Jobs’ last prediction isn’t referring to:
- Tesla or self-driving cars
- Cloud computing
- The blockchain or cryptocurrencies
- Virtual reality
- Space exploration
- Artificial intelligence
Hidden Alpha‘s Joel Litman says he’s seeing signs that Jobs may have been right. And the resulting shift could have a tremendous impact on every corner of the global economy.
He and his team have developed a new research package for a chance to make the most of this opportunity.
Before we dig into the specifics of Jobs’ final prediction and Joel’s research, let’s take a look at Steve’s background.
Who Is Steve Jobs?
Steve Jobs was a visionary entrepreneur with keen foresight and an eye for innovation.
Today, Apple, the tiny company he founded in his garage, is worth upwards of $1 trillion.
His visionary status was earned by his uncanny ability to anticipate the future of tech and other fields.
He accurately predicted many of the most consequential inventions and investment trends of recent memory, including:
- The advent of cloud computing
- GUI-controlled personal computer
- Development of laptops
- The shift away from prompt-based operating systems
- Siri and Alexa voice assistants
- And other digital technologies
Over many years in the entrepreneurial spotlight, Jobs developed a cult-like following, and he’s hailed as a genius for his insight and cunning.
He was the driving force behind several technological advancements that wowed users and even his competitors.
His company, Apple, launched the first successful mass-produced computers with a graphic user interface. Jobs’ team also developed Apple Lisa, a popular operating system named after his daughter.
Since then, Apple has been a leading computer manufacturer, competing with the likes of Microsoft.
Its devices, software, and apps, such as the iPod, iTunes, and Mac, have altered the technological and e-commerce landscape.
Jobs continued to play a crucial role throughout much of the company’s life. And after being fired by the board back in 1985, he returned nearly 11 years later to usher in a new era of tech dominance.
Much to the delight of its investors, the floundering Apple also experienced record profitability.
A SynBio Boom?
The last words of Steve Jobs about the intersection of technology and biology seem to be coming true.
The first major milestone came in January 2020 when researchers remotely sequenced the virus responsible for the COVID-19 pandemic.
Researchers used this digital model to isolate the spike protein that would eventually be used to develop an mRNA vaccine to prevent the disease. Joel Litman believes this underreported event marked the beginning of a new era centered around collaboration between technology and biology.
This budding industry is known as SynBio.
And Joel believes it could have an enormous impact on the entire global economy and fuel a new era of growth.
The Case for SynBio
Joel believes that SynBio could be one of the most significant advancements since the internet launched the tech boom.
He also says that, right now, the tech might be at an inflection point that could change the landscape of several industries.
Some examples of potential technologies include self-healing rubber, humane animal-based insulin, sustainable energy (such as solar), and much more.
Now could be a great time to get in on this under-the-radar tech, especially while much of the market is still stuck on 5G, electric cars, space exploration, artificial intelligence, virtual reality, etc.
Don’t get us wrong, EVs, AI, and the lot are fantastic, but they’re technologies dominating today’s headlines: everyone is already in the know. Some of the biggest investment gains come from getting in before the boom.
Plus, with so many big-named digital technology stocks crashing, it might be time to turn focus on companies for the potential for real growth.
SynBio tech has endless potential; just as Steve Jobs predicted, it could revolutionize the world. As it was with the last tech boom, early entries could see massive returns.
Some companies are pioneering game-changing SynBio technology and building next-gen ecosystems like Amazon and Facebook.
And with so many tech stocks crashing, many folks are looking for a new angle on the market.
Fortunately, Joel Litman has identified several companies trading on the stock market right now that could dominate their industries in the years ahead.
He has assembled his work into a collection of exclusive reports as part of his new research package for Hidden Alpha. Altogether, they feature five of his top-rated SynBio stocks.
Who Is Joel Litman?
Joel Litman is a seasoned finance veteran and one of the world’s leading forensic accounting experts, and he leads Hidden Alpha.
His expertise is a valuable asset for readers. He has a knack for pinpointing promising large-cap stocks that the mainstream market has overlooked, and members get first-hand access to his latest findings.
Joel has built a solid track record throughout his career and earned widespread respect in his field.
Today, he serves as the Chief Investment Strategist for Hidden Alpha‘s publisher, Altimetry. And he holds the title of CEO and President at Atimetry’s parent company, Valens Research.
Joel has appeared on CNBC, and Barron’s and Institutional Investor have both quoted him in their articles. He’s even been published in the Harvard Business Review!
What Is Hidden Alpha?
Hidden Alpha is a research service and monthly newsletter from Altimetry and forensic accounting specialist Joel Litman.
Altimetry is a research firm and sister company to Empire Financial Research, publishers of Empire Financial Daily.
The service primarily focuses on promising, undervalued large-cap stocks that Joel has identified through extensive financial analysis.
We have an in-depth Hidden Alpha review, but it’s not required reading for this package.
Members also enjoy a wide array of additional benefits, including new stock recommendations every month, access to a complete model portfolio, and more.
If you sign up under the new deal, you get a 12-month subscription to Hidden Alpha with your purchase, including the full assortment of member benefits.
What Comes with the Service?
The latest package is stacked with an assortment of solid features.
Read on to find out everything you get.
As a member, you’ll receive Joel Litman’s latest stock picks, research, and analysis right in your inbox on the first Monday of every month.
He keeps you informed on all the latest market-moving news, and you’ll be the first to know if he discovers another promising SynBio stock.
Updates and Alerts
The team sends out alerts whenever it’s time to make a move. You’ll receive both buy and sell alerts as part of your subscription.
You’ll also receive updates on the stocks featured in the model portfolio so you can stay up to speed on each recommendation’s progress.
Hidden Alpha Model Portfolio
A membership also includes unlimited access to the newsletter’s model portfolio that features his active stock recommendations.
The model portfolio includes details on each recommended stock, including its name, ticker symbol, price target, and more.
Joel Litman’s Research Archives
You can tap into an archive containing the entire collection of Joel Litman’s research for Hidden Alpha, including his previous special reports and much more.
SynBio is today’s hot trend, but Joel has shared tons of valuable insights over the course of his tenure.
And the archives give you first-hand access to all of it.
New Member Bonuses
This bundle includes exclusive special reports focusing on highly rated SynBio stocks.
Here’s what’s covered in each brief:
My Favorite SynBio Investment Right Now
The featured report in the collection includes in-depth analysis of Joel’s favorite SynBio play, Illumina.
As covered above, this company is a leading player in the DNA sequencing industry and has demonstrated tremendous promise over the past couple of years.
Profiting From the NEXT Big SynBio Wave
Buying Illumina is just one way to play the SynBio boom.
According to Joel, buying the next big wave of winners is another important part of the strategy. He has identified two SynBio-platform companies that could have tremendous upside and lays out his findings in this bonus report.
Buy the Platforms — Your Best Shot at a 1,000% Winner
The tech boom taught us that platforms like Facebook, Google, and Amazon can grow rapidly when a transformative trend takes off
And SynBio might follow suit.
Joel believes companies that create and host ecosystems that effectively harness SynBio innovations could be in the same class as the Big Tech behemoths that dominate today’s market.
The Perfect Portfolio
Litman has assembled a mock portfolio featuring his top picks in the SynBio sector, and your Hidden Alpha subscription includes unlimited access to this valuable resource.
The portfolio showcases each stock’s name along with its ticker symbol, price target, current recommendation, and much more.
Litman’s Perfect Portfolio serves as an excellent model, and it can help you squeeze every drop of potential profits out of the SynBio revolution.
BONUS Subscription to Altimetry Daily Authority
Each issue of this market daily newsletter will be sent to you every day ahead of the opening bell.
Between the monthly Hidden Alpha newsletter, updates from the team, and the Altimetry Daily Authority, you’ll have a constant stream of professional-grade research at your disposal.
Under the latest deal, subscriptions include a 100% money-back guarantee from Joel.
This means you have an entire 30 days to test drive the service. If you’re not a fan, you can get a full refund.
Simply contact the member services team within 30 days of your purchase and let them know you’re not satisfied. Then, they’ll issue a full refund for your subscription cost.
How Much Does It Cost?
You can sign up under the latest deal at a substantially discounted rate.
Typically, a one-year subscription to Hidden Alpha costs $199, but our readers can access a special reduced rate.
If you sign up now, you’ll pay just $49 for the complete bundle. That’s a 75% discount on the sticker price.
Better yet, you’ll still get all the bonus reports covered in this review, including Joel Litman’s top-5 SynBio stock recommendations.
Hidden Alpha is a great monthly research service in its own right, but the latest deal is a downright bargain. You get a full year of the newsletter, plus a treasure trove of additional research.
Joel Litman’s top-rated SynBio stocks and his Perfect Portfolio could put you in an excellent position to benefit from this unfolding tech trend.
With monthly newsletters, regular updates, and a bonus market daily e-letter, you have an arsenal of investing insights from top-rated experts at your disposal every time the market is in session.
Just as Steve Jobs’ “Final Prophecy” predicted, SynBio could be an enormous growth industry, and this package equips you to make the most of the opportunity.